Reindeer Biotech

Reindeer Biotech is a clinical-stage biopharmaceutical company specializing in the development of innovative cell therapies and antibody drugs for oncology and autoimmune diseases. The company's lead product, equecabtagene autoleucel, is a fully human BCMA-directed CAR-T cell therapy that has received regulatory approval in China for relapsed or refractory multiple myeloma. Reindeer Biotech utilizes its proprietary fully human antibody discovery platform and high-throughput CAR-T screening technology to maintain a competitive pipeline. Their research focus includes targeting BCMA, CD19, CD22, and GPRC5D for various hematological malignancies and autoimmune conditions like neuromyelitis optica spectrum disorder. The company operates integrated facilities for research, development, and clinical-grade GMP manufacturing across China and the United States. Reindeer Biotech continues to expand its therapeutic reach by exploring CAR-T applications in solid tumors and chronic inflammatory diseases.